Biofarm (H3D) Stock Overview

Manufactures and sells medicines in Romania. More details

H3D fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	5/6
Financial Health	5/6
Dividends	5/6

Rewards

Trading at 14.6% below our estimate of its fair value

Earnings grew by 17.1% over the past year

Pays a reliable dividend of 2.84%

Risk Analysis

Volatile share price over the past 3 months compared to the German market

H3D Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Biofarm S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biofarm
Historical stock prices
Current Share Price	RON 0.26
52 Week High	RON 0.26
52 Week Low	RON 0.21
Beta	0.50
1 Month Change	3.56%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	16.44%

Recent updates

Shareholder Returns

	H3D	DE Pharmaceuticals	DE Market
7D	1.9%	3.9%	-0.9%
1Y	n/a	29.3%	1.9%

Return vs Industry: Insufficient data to determine how H3D performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how H3D performed against the German Market.

Price Volatility

Is H3D's price volatile compared to industry and market?
H3D volatility
H3D Average Weekly Movement	9.2%
Pharmaceuticals Industry Average Movement	5.8%
Market Average Movement	5.8%
10% most volatile stocks in DE Market	13.4%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: H3D's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine H3D's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1921	374	Catalin Vicol	www.biofarm.ro

Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescription medicines, food supplements, medical devices, cosmetics, medical devices, and other products.

Biofarm S.A. Fundamentals Summary

How do Biofarm's earnings and revenue compare to its market cap?
H3D fundamental statistics
Market cap	€278.57m
Earnings (TTM)	€19.26m
Revenue (TTM)	€60.51m

14.5x

P/E Ratio

4.6x

P/S Ratio

Is H3D overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
H3D income statement (TTM)
Revenue	RON 316.75m
Cost of Revenue	RON 46.17m
Gross Profit	RON 270.58m
Other Expenses	RON 169.74m
Earnings	RON 100.84m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 14, 2026

Earnings per share (EPS)	0.10
Gross Margin	85.42%
Net Profit Margin	31.84%
Debt/Equity Ratio	0.2%

How did H3D perform over the long term?

See historical performance and comparison

Dividends

2.8%

Current Dividend Yield

41%

Payout Ratio

Does H3D pay a reliable dividends?

See H3D dividend history and benchmarks

When do you need to buy H3D by to receive an upcoming dividend?
Biofarm dividend dates
Ex Dividend Date	Jun 29 2026
Dividend Pay Date	Jul 10 2026
Days until Ex dividend	5 days
Days until Dividend pay date	16 days

Does H3D pay a reliable dividends?

See H3D dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/22 00:38
End of Day Share Price	2026/06/19 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biofarm S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Vladimira Urbankova	Erste Group Bank AG
Raluca Florea	Erste Group Bank AG

Biofarm S.A.DB:H3D Stock Report